The potentiality of histone deacetylase inhibitors for diabetes and obesity

El-Serafi, Ahmed Taher,1977-Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten (author)

Diabetes, obesity, and metabolic syndrome represent the current global epidemic. In spite of the continuous development of related pharmaceuticals, complications of these conditions lower the patient's life quality and cause a burden on the health economy. Histone deacetylase inhibitors are slowly emerging as a line of management for several medical conditions. Many studies have described their potential role in diabetes, in terms of enhancing insulin secretion and decreasing insulin resistance. In obesity, these agents showed a very interesting role in converting white fat cells to their brown counterpart, as well as shifting the metabolic pathways toward less adiposity. Although these effects are characterized at the cellular and preclinical levels, few clinical studies have been reported. This chapter includes an overview of the relation between histone deacetylation and the development of diabetes and obesity, as well as the possible future role of histone deacetylase inhibitors in the management of these conditions.

El Serafi, Ibrahim TaherDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden(Swepub:liu)ibrel65 (author)
Linköpings universitetAvdelningen för kirurgi, ortopedi och onkologi (creator_code:org_t)

In:Histone Modifications in TherapySan Diego, United states : Elsevier, s. 361-3719780128164228

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.